teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 4 Projects Releases Packages Wiki Activity Actions 1

extract: 2026-03-30-eurheartj-select-mediation-analysis-esc-2024
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details

Browse source 
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
This commit is contained in:
Teleo Agents 2026-03-30 04:45:54 +00:00
parent 544721105a
commit 8c2416f9bb
2 changed files with 21 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

6
domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
View file

@ -25,6 +25,12 @@ This has major implications: (1) the drug should benefit patients across the BMI
---
### Additional Evidence (confirm)
*Source: [[2026-03-30-eurheartj-select-mediation-analysis-esc-2024]] | Added: 2026-03-30*
ESC 2024 mediation analysis quantifies specific mediator contributions: hsCRP (inflammation) accounts for 42.1% of CV benefit, body weight only 19.5%, waist circumference 64.0%. Joint mediation of ALL measured factors (weight, inflammation, HbA1c, waist) explains only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% unexplained. This confirms the weight-independence finding from the Lancet 2025 prespecified analysis and adds the specific breakdown showing inflammation mediates MORE than weight loss.
Relevant Notes:
- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]

16
inbox/queue/2026-03-30-eurheartj-select-mediation-analysis-esc-2024.md
View file

@ -7,9 +7,13 @@ date: 2024-09-01
domain: health
secondary_domains: []
format: conference-abstract
status: unprocessed
status: enrichment
priority: medium
tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, mediation-analysis, ESC-2024, inflammation, hsCRP, weight-independent]
processed_by: vida
processed_date: 2026-03-30
enrichments_applied: ["semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
---
## Content
@ -52,3 +56,13 @@ tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, mediation-analysis, ESC
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
WHY ARCHIVED: Complementary to Lancet 2025 prespecified analysis. Provides specific mediator percentages (hsCRP 42.1%, body weight 19.5%) that the Lancet analysis doesn't separately report.
EXTRACTION HINT: Extract as SECONDARY EVIDENCE for the mechanism claim. The Lancet 2025 analysis (queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md) is the primary source. Use this for the specific hsCRP/body weight percentage breakdown which the Lancet paper doesn't separately quantify. Wide CIs = flag for confidence calibration.
## Key Facts
- SELECT trial mediation analysis presented at ESC Congress 2024
- hsCRP mediation estimate: 42.1%
- Body weight mediation estimate: 19.5%
- Waist circumference mediation estimate: 64.0% (widest confidence interval)
- HbA1c mediation estimate: 29.0%
- Joint mediation of all measured factors: 31.4% (95% CI: -30.1% to 143.6%)
- All measured mediators showed statistically significant improvements with semaglutide